A Clinical Study of the Safety and Efficacy of CD19/BCMA CAR-T Cell Therapy for Refractory/Relapsed Lupus Nephritis
Latest Information Update: 24 Jan 2025
Price :
$35 *
At a glance
- Drugs Anti-CD19 and anti-BCMA CART cell therapy-Yake Biotechnology (Primary)
- Indications Lupus nephritis
- Focus Adverse reactions
- 24 Jan 2025 New trial record